A two-year experience with Norplant implants in Assiut, Egypt.
This report describes the two-year experience of 250 acceptors of NORPLANT implants and 100 TCu-380-Ag IUD acceptors in Assiut, Egypt. The two-year net continuation rate was 67.9 per 100 for implant users and 52.3 per 100 for IUD users. The most important cause for NORPLANT removal was the disruption of menstrual rhythm. However, by the end of the second year, three-quarters of NORPLANT users had monthly menstrual periods and about 60 percent described the amount of blood loss as average, 15 percent as decreased, 15 percent as increased and 10 percent as variable. About 88 percent of the NORPLANT acceptors rated their experience with the contraceptive as good or excellent.
D000328:Adult; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000009:adverse effects; D003692:Delayed-Action Preparations; D004343:Drug Implants; D004534:Egypt; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007435:Intrauterine Devices, Copper / Q000009:adverse effects*; D016912:Levonorgestrel; D008599:Menstruation Disturbances / Q000209:etiology*; D009644:Norgestrel / Q000008:administration & dosage / Q000009:adverse effects*; D011247:Pregnancy; D011275:Pregnancy, Unwanted; D012826:Silicone Elastomers
D003277:Contraceptives, Oral, Combined; D003692:Delayed-Action Preparations; D004343:Drug Implants; D012826:Silicone Elastomers; D009644:Norgestrel; D016912:Levonorgestrel